Analysis of the cost-effectiveness of liquid biopsy to determine treatment change in patients with her2-positive advanced breast cancer in Colombia
Background: Breast cancer is highly prevalent worldwide and leads to high health-care costs. HER2-positive subtype represents 30% of all breast cancers and is associated with a poor prognosis. Patients treated with anti-HER2 therapies frequently develop resistance and require pharmacological treatme...
- Autores:
-
Sánchez-Calderón, Diana
Pedraza A, Mancera Urrego C
Mejía-Mejía, Aurelio
Montealegre Paez, Ana Lorena
Perdomo Lara, Sandra Janneth
- Tipo de recurso:
- Fecha de publicación:
- 2020
- Institución:
- Universidad El Bosque
- Repositorio:
- Repositorio U. El Bosque
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.unbosque.edu.co:20.500.12495/2002
- Palabra clave:
- Neoplasias de la mama
Resistencia a antineoplásicos
Costos de los medicamentos
Cost-effectiveness
Liquid biopsy
Biomarkers
- Rights
- License
- Attribution-NonCommercial 4.0 International